The author presents an overview of the current literature on homocysteine as a risk factor for neuropsychiatric disorders. The databases MEDLINE, Current Contents and EMBASE were searched (between 1966 and 2002) for English language publications with the key words 'Homocysteine' and 'Stroke'; 'Alzheimer Disease'; 'Cognitive Impairment'; 'Epilepsy'; 'Depression'; or 'Parkinson's disease'. Indivi...

Apathy is a common neurobehavioral feature in a variety of neuropsychiatric disorders. Apathy is often interpreted as a sign of deppression or as a nonspecific symptom of other medical conditions. However, recent research indicates that the essential meaning of apathy is lack of motivation. This article presents a frame work for the classification and differential diagnosis of apathy and addres...

We read with interest the Article by Maxime Taquet and colleagues1Taquet M Geddes JR Husain Luciano S Harrison PJ 6-month neurological psychiatric outcomes in 236 379 survivors of COVID-19 : a retrospective cohort study using electronic health records.Lancet Psychiatry. 2021; 8: 416-427Summary Full Text PDF PubMed Scopus (827) Google Scholar The Lancet Psychiatry that evaluated large population...

INTRODUCTION We used data from the Global Burden of Disease, Injuries, and Risk Factors Study 2010 to report on the burden of neuropsychiatric disorders in Spain. MATERIALS AND METHODS The summary measure of burden used in the study was the disability-adjusted life-year (DALY), which sums of the years of life lost due to premature mortality (YLLs) and the years lived with disability (YLDs). D...

Assessing human cerebrospinal fluid (CSF) provides a practical way to conduct longitudinal molecular analyses of changes during the course of neurological disease. Integrated and parallel analyses of neurotransmitters, neuropeptides and proteins in CSF may reveal better insights into complex interaction of numerous cell types in the central nervous system (CNS) at an unprecedented level of comp...

Because GABA appears to be an important, if not the primary, inhibitory neurotransmitter in brain, it is not surprising to find biochemical, physiological and behavioral data indicating that activation of the GABAergic system may be efficacious in the treatment of epilepsy (Meldrum, 1975). In addition, a significant loss of GABA neurons has been noted around the seizure foci in monkey cortex af...